Weissman was jointly awarded the 2023 Nobel Prize in Medicine with Katalin Karikó for discoveries which made COVID-19 ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny ...

Weight trajectories differed significantly among patients with HIV during the first year of ART, with no associations observed between weight gain and type of ART regimen.

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

Key findings from the trial include durable viral suppression, with 94% of participants maintaining RNA levels below 50 ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...